entacapone tablet

INDICATIONS Entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with Parkinson’s disease (see CLINICAL PHARMACOLOGY, Clinical Studies). Entacapone tablets effectiveness has not been systematically evaluated in patients with Parkinson’s disease who do not experience end-of-dose “wearing-off”.

macleods pharmaceuticals limited

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] nausea` `[3] fatigue` `[4] diarrhoea` `[5] off label use` `[6] dyspnoea` `[7] pain` `[8] headache` `[9] vomiting` `[10] pyrexia`

6 years ago

OVAL BROWN L7

HOW SUPPLIED

ENTACAPONE USP is supplied as 200 mg film-coated tablets for oral administration. The brown colored, oval shaped, biconvex, film coated tablets are debossed with “L7” on one side and plain on other side. Tablets are provided in HDPE containers as follows: Bottles of 100…………………… NDC 33342-260-11 Bottles of 500…………………… NDC 33342-260-15 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature] Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540 Manufactured by: Macleods Pharmaceuticals Ltd. Baddi, Himachal Pradesh, INDIA Revised: July 2022

More pills like OVAL L7